Aerosol from tobacco

Patent metadata

Field	Value
Publication number	US-10779570-B2
Application number	US-201414764054-A
Country	US
Kind code	B2
Filing date	Jan 30, 2014
Priority date	Jan 30, 2013
Publication date	Sep 22, 2020
Grant date	Sep 22, 2020

Abstract

In one aspect, there is provided a method of administering nicotine to a user via inhalation of the nicotine through an aerosol generating device comprising the steps of: (a) providing an aerosol-generating device in which tobacco contained in the aerosol-generating device is electrically heated to a temperature of less than about 400 degrees Celsius; and (b) allowing the user to inhale the aerosol derived from the electrically heated tobacco; wherein the aerosol contains levels of nicotine that are about the same as the levels in combusted tobacco; and wherein the level of one or more harmful or potentially harmful constituents (HPHCs) other than nicotine in the aerosol is lower than the level in combusted tobacco.

First claim

The invention claimed is:

1. A method of inhaling an aerosol comprising nicotine through an aerosol generating device comprising the steps of:
(a) providing an aerosol-generating device in which tobacco contained therein is electrically heated by an internal heating element to a temperature of between 325 and 390 degrees Celsius to create an aerosol without combusting the tobacco, wherein the internal heating element is in the form of a pin or blade; and
(b) allowing a user to inhale the aerosol derived from the electrically heated tobacco, wherein the aerosol passes over and is cooled by an aerosol-cooling element before being inhaled by the user, and the aerosol-cooling element (i) has a total surface area of 300 to 1000 square millimeters per millimeter length and/or (ii) comprises a plurality of longitudinally extending channels;
wherein the aerosol contains levels of nicotine that are at least about 70% of the levels in combusted tobacco of reference cigarette 3R4F; and
wherein the aerosol contains levels of one or more harmful or potentially harmful constituents (HPHCs) other than nicotine that are lower than the levels in combusted tobacco of reference cigarette 3R4F on a per mg of nicotine basis.

2. The method according to claim 1 , wherein one or more HPHCs other than nicotine are not detectable or are not appreciably detectable in the aerosol generated by the electrically heated tobacco, said HPHCs being selected from the group consisting of: m-cresol, p-cresol, 1,3 butadiene, isoprene, acrylonitrile, benzene, 1-aminonaphthalene, 2-aminonaphthalene, 3-aminobiphenyl, 4-aminobiphenyl, cyanhydric acid and cadmium or a combination of one or more thereof or a combination thereof.

3. The method according to claim 1 , wherein 4-aminobiphenyl, 2-aminonaphthalene and 1-aminonaphthalene are present in the aerosol at up to or less than about 0.1 ng/mg nicotine; wherein carbon monooxide, 1,3-butadiene, benzene, benzoprene and acrylonitrile are present in the aerosol at between about 0.4 and 0.11 ng/mg nicotine; wherein isoprene, toluene, formaldehyde and crotonaldehyde are present in the aerosol at between about 1.5 and 3 ng/mg nicotine; wherein N-nitrosonornicotine and NNK are present in the aerosol at between about 3.1 and 5 ng/mg nicotine; wherein acrolein is present in the aerosol at between about 4 and 7 ng/mg nicotine; wherein ammonia is present in the aerosol at between about 9 and 11 ng/mg nicotine; and wherein acetaldehyde is present in the aerosol at between about 100 and 160 ng/mg nicotine.

4. The method according to claim 1 , wherein the levels of any one of carbon monoxide, benzene, acrolein and 1,3-butadiene or biomarkers thereof in the user of the aerosol-generating device are lower than the levels in the user when generated from combusted tobacco, suitably, wherein
the carboxyhemoglobin (carbon monoxide marker) level in the user is between about 1-2%, suitably about 1.5% in blood after 1 day of consuming aerosol generated from electrically heated tobacco; and/or
the S-PMA (benzene marker) level in the user is between about 0.1 to 1 micro·g/g creatinine, suitably about 0.5 micro·g/g creatinine in urine after 2 days of consuming aerosol generated from electrically heated tobacco; and/or
the 3-HPMA (acrolein marker) level in the user is between about 200 to 400 micro·g/g creatinine, suitably, about 300 micro·g/g creatinine in urine after 2 days of consuming aerosol generated from electrically heated tobacco; and/or
the MHBMA (1,3-butadiene marker) level in the user is about 0.1 to 1 micro·g/g creatinine, suitably 0.5 micro·g/g creatinine in urine after 2 days of consuming aerosol generated from electrically heated tobacco.

5. The method according to claim 1 , wherein the profile of nicotine delivery via inhalation of the aerosol generated by electrically heated tobacco is substantially the same as that obtained via inhalation of an aerosol generated from combusted tobacco, suitably, wherein the concentration of nicotine in the blood plasma increases to a maximum concentration within about 9 minutes of inhaling the aerosol from electrically heated tobacco; and/or wherein the t max is between about 7 and 9 minutes; and/or wherein mean AUC 0-∞ and AUC 0-t′ , is between about 18 and 20 ng·h/mL and between about 0.5 and 0.6 ng·h/mL, respectively.

6. The method according to claim 1 , wherein the heating element that electrically heats the tobacco is inserted into the tobacco and wherein a continuous supply of energy is supplied to the heating element, said continuous supply of energy being monitored during use of the device.

7. The method according to claim 2 , wherein 4-aminobiphenyl, 2-aminonaphthalene and 1-aminonaphthalene are present in the aerosol at up to or less than about 0.1 ng/mg nicotine; wherein carbon monooxide, 1,3-butadiene, benzene, benzo[a]prene and acrylonitrile are present in the aerosol at between about 0.4 and 0.11 ng/mg nicotine; wherein isoprene, toluene, formaldehyde and crotonaldehyde are present in the aerosol at between about 1.5 and 3 ng/mg nicotine; wherein N-nitrosonornicotine and NNK are present in the aerosol at between about 3.1 and 5 ng/mg nicotine; wherein acrolein is present in the aerosol at between about 4 and 7 ng/mg nicotine; wherein ammonia is present in the aerosol at between about 9 and 11 ng/mg nicotine; and wherein acetaldehyde is present in the aerosol at between about 100 and 160 ng/mg nicotine.

8. The method according to claim 7 , wherein the levels of any one of carbon monoxide, benzene, acrolein and 1,3-butadiene or biomarkers thereof in the user of the aerosol-generating device are lower than the levels in the user when generated from combusted tobacco, suitably, wherein
the carboxyhemoglobin (carbon monoxide marker) level in the user is between about 1-2%, suitably about 1.5% in blood after 1 day of consuming aerosol generated from electrically heated tobacco; and/or
the S-PMA (benzene marker) level in the user is between about 0.1 to 1 micro·g/g creatinine, suitably about 0.5 micro·g/g creatinine in urine after 2 days of consuming aerosol generated from electrically heated tobacco; and/or
the 3-HPMA (acrolein marker) level in the user is between about 200 to 400 micro·g/g creatinine, suitably, about 300 micro·g/g creatinine in urine after 2 days of consuming aerosol generated from electrically heated tobacco; and/or
the MHBMA (1,3-butadiene marker) level in the user is about 0.1 to 1 micro·g/g creatinine, suitably 0.5 micro·g/g creatinine in urine after 2 days of consuming aerosol generated from electrically heated tobacco.

9. The method according to claim 8 , wherein the profile of nicotine delivery via inhalation of the aerosol generated by electrically heated tobacco is substantially the same as that obtained via inhalation of an aerosol generated from combusted tobacco, suitably, wherein the concentration of nicotine in the blood plasma increases to a maximum concentration within about 9 minutes of inhaling the aerosol from electrically heated tobacco; and/or wherein the t max is between about 7 and 9 minutes; and/or wherein mean AUC 0-∞ and AUC 0-t′ , is between about 18 and 20 ng·h/mL and between about 0.5 and 0.6 ng·h/mL, respectively.

10. The method according to claim 9 , wherein the heating element that electrically heats the tobacco is inserted into the tobacco and wherein a continuous supply of energy is supplied to the heating element, said continuous supply of energy being monitored during use of the device.

Assignees

• Philip Morris Products Sa

Inventors

• Fernando Felix
• Greim Olivier
• Haziza Christelle
• Lama Nicola
• Radtke Falk

Classifications

• A24F40/80 Primary

  Testing · CPC title

• A24F40/20

  Devices using solid inhalable precursors · CPC title

• A24F40/46

  Shape or structure of electric heating means · CPC title

• H01J49/0036

  Step by step routines describing the handling of the data generated during a measurement · CPC title

• A24F47/008 Primary

  Human Necessities · mapped topic